Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

Simcere will receive a $15 million upfront payment,and up to $492 million in development and commercial milestone payments considering successful achievements in several indications,with an important part as sales milestones,as well as up to low double-digit tiered royalties based upon future global sales

Under the agreement,Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region

SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu-Fc) that selectively activates regulatory T cells. As an IND ready subcutaneous injection,it can be developed to potentially treat various autoimmune diseases

NANJING,China,Sept. 29,2022 -- Simcere Pharmaceutical Group (2096.HK),an innovation and R&D-driven pharmaceutical company,and Almirall S.A. (BME: ALM),a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate,SIM0278.

Under the agreement,Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region (Mainland China,Hong Kong,Macau and Taiwan). Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.

Within the terms of the agreement,Simcere will receive a $15 million upfront payment,as well as up to low double-digit tiered royalties based upon future global sales.

"We are very excited to have reached a collaborative agreement with Almirall for the development of SIM0278. This innovative IL-2 mutein is one important molecule of our immune-rebalancing strategy for autoimmune diseases." Said Renhong Tang,Ph.D.,Co-CEO of Simcere,"SIM0278 is one of the key molecules developed based on Simcere's in-house protein engineering platform. This partnership also marks a milestone of Simcere's globalization effort. We look forward to closely working with Almirall to demonstrate the clinical value of SIM0278.

"At Almirall,we always look for new opportunities to strengthen our R&D pipeline. That is why we are very pleased to close this new development and commercialisation agreement with Simcere,"statedKarl Ziegelbauer,Almirall's Chief Scientific Officer."SIM0278 has great potential to treat a broad spectrum of immunological diseases,and we expect that its development will allow us to reinforce our biologic pipeline and our leading position in Medical Dermatology.

About SIM0278

SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu-Fc) that activates regulatory T cells developed in-house by utilizing Simcere's protein engineering platform. This IND ready subcutaneous injection will potentially be developed to treat various autoimmune diseases. SIM0278 exhibits improved PK profile and selective activation of Treg cells with no activation of effector T cells or NK cells to restore immune balance which has been demonstrated in multiple preclinical disease models.

About Simcere

Simcere Pharmaceutical Group Limited (2096.HK) is an innovation and R&D-driven pharmaceutical company. The company focuses on three therapeutic areas,oncology,central nervous system and autoimmune diseases,with a forward-looking vision toward disease areas that may have significant clinical needs in the future,aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence,Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.www.Simcere.com

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company,founded in 1943 and headquartered in Barcelona,is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history,Almirall has retained a strong focus on the needs of patients. Currently,Almirall has a direct presence in 21 countries and strategic agreements in over 70.

For more information,please visitalmirall.com

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts,figures and opinions contained in this document,in addition to the historical ones,are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore,actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements,goals or estimates contained in this document to reflect any changes in the assumptions,events,or circumstances on which such forward-looking statements are based,unless required by the applicable law.

View original content:https://www.prnewswire.com/news-releases/simcere-and-almirall-enter-into-a-licensing-agreement-for-il-2-mu-fc-301636314.html